Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.59 |
| ▸ | PDE4A | P27815 | 1/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | MPI | P34949 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9647920 | 0.98 | ALOX5 (0.57) | ALOX5PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL26646796 | 0.95 | ALOX5 (0.61) | ALOX5PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2274341 | 0.81 | ALOX5 (0.63) | ALOX5MPI | |
| SCHEMBL10484805 | 0.79 | GAA (0.65) | PDE4APDE4BPDE4CPDE4DLMNA | |
| SCHEMBL25408148 | 0.78 | ALOX5 (0.59) | ALOX5MPI | |
| SCHEMBL22075748 | 0.78 | ALOX5 (0.59) | ALOX5MPI | |
| SCHEMBL9646406 | 0.76 | ALOX5 (0.53) | ALOX5MPI | |
| SCHEMBL8652560 | 0.75 | MPO (0.72) | — | |
| SCHEMBL2673327 | 0.75 | ALOX5 (1.00) | ALOX5MPI | |
| SCHEMBL30336436 | 0.75 | ALOX5 (1.00) | ALOX5MPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011057993-A1 | INDAZOLONE DERIVATIVES AS GLYCOGEN SYNTHASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-19 | — | — | WO | disclosed |
| US-20110112147-A1 | INDAZOLONE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112147-A1 | INDAZOLONE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, GYS1, PYGL | ALOX5 2925/4885PDE4A 603/4885PDE4B 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.